Free Trial

Evotec (OTCMKTS:EVTCY) Share Price Crosses Below Fifty Day Moving Average - Time to Sell?

Evotec logo with Medical background
Remove Ads

Evotec SE (OTCMKTS:EVTCY - Get Free Report) passed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $4.31 and traded as low as $3.58. Evotec shares last traded at $3.64, with a volume of 29,161 shares changing hands.

Evotec Price Performance

The company has a market cap of $1.12 billion, a price-to-earnings ratio of 8.27 and a beta of 0.98. The company has a current ratio of 2.57, a quick ratio of 2.50 and a debt-to-equity ratio of 0.53. The business has a 50-day moving average price of $4.26 and a 200 day moving average price of $4.23.

About Evotec

(Get Free Report)

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties.

Read More

Should You Invest $1,000 in Evotec Right Now?

Before you consider Evotec, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.

While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

HIMS Stock Up 120%! More Growth Ahead?

HIMS Stock Up 120%! More Growth Ahead?

Hims & Hers (NYSE: HIMS) has skyrocketed 120% in just a month! Is it the next big disruptor in healthcare, or is it overpriced?

Recent Videos

 5 Stocks to BUY NOW in April 2025
3 Bank Stocks Defying Market Turmoil—Cheap Options Trades!
Time to Buy SoFi? Fintech’s Next Big Move

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads